Previous Close | 0.8523 |
Open | 0.8687 |
Bid | 0.8411 x 900 |
Ask | 0.8688 x 800 |
Day's Range | 0.8202 - 0.8687 |
52 Week Range | 0.6950 - 2.1700 |
Volume | |
Avg. Volume | 135,950 |
Market Cap | 40.222M |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8910 |
Earnings Date | Mar 08, 2023 - Mar 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for CRVS
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE N
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, along with an update